Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00323739 · ClinicalTrials.gov registry record · Phase 2
Bevacizumab (Avastin) and RAD001(Everolimus)in the Treatment of Advanced Clear Cell Renal Carcinoma
A Phase 2 study, sponsored by SCRI Development Innovations.
- Completed
- Registry status
- Phase 2
- Development phase
- 80
- Enrollment target
NCT00323739 is a Phase 2 study that has completed, run by SCRI Development Innovations. The registered enrollment target is 80 participants.
The verdict
NCT00323739, a Phase 2 study, has completed, sponsored by SCRI Development Innovations.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 80 participants
- Enrollment target
Study Summary
This phase II trial will evaluate the combination of bevacizumab + RAD001 in patients with metastatic renal cell carcinoma. In this trial the investigators will evaluate this combination in patients previously untreated with any anti-angiogenesis agent and patients who have previously received one prior regimen containing an anti-angiogenesis agent.
Interventions
- DRUG bevacizumab
- DRUG RAD001
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 80 participants |
| Start Date | 2006-05 |
| Est. Completion | 2011-03 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00323739
The ClinicalTrials.gov registry entry for NCT00323739 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 80 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is SCRI Development Innovations, which has 146 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which bevacizumab is the first listed.
NCT00323739 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00323739 about?
NCT00323739 is a clinical study titled "Bevacizumab (Avastin) and RAD001(Everolimus)in the Treatment of Advanced Clear Cell Renal Carcinoma". This phase II trial will evaluate the combination of bevacizumab + RAD001 in patients with metastatic renal cell carcinoma. In this trial the investigators will evaluate this combination in patients previously untreated with any anti-angiogenesis agent and patients who have previously received one p...
What is the current status of trial NCT00323739?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 80 participants. The study started on 2006-05. Estimated completion is 2011-03.
What interventions are being tested in trial NCT00323739?
The interventions under investigation include: bevacizumab (DRUG), RAD001 (DRUG).
Who is sponsoring clinical trial NCT00323739?
This trial is sponsored by SCRI Development Innovations, which has 146 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.